Positively Aware HIV Drug Guide: Cabenuva


cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension CAB-LA (long-acting injectable INSTI)/RPV LA (long-acting injectable NNRTI)

Complete HIV regimen DHHS recommended for people with viral suppression
Long-Acting Regimen

Standard Dose

Two long-acting intramuscular gluteal (butt muscle) injections once every two months. May be taken once monthly. Cabenuva consists of one injection of long-acting cabotegravir and one injection of long-acting rilpivirine. No food restrictions.

For adults and adolescents age 12 and older weighing at least 77 pounds (35 kg) who are switching from a stable HIV regimen and have undetectable viral load (less than 50 copies per mL) with no history of antiretroviral treatment failure, no active hepatitis B infection, and no drug resistance or suspected resistance to cabotegravir or rilpivirine. A month of daily oral lead-in therapy may be recommended before injections begin, consisting of a 30 mg tablet of cabotegravir (Vocabria) and a 25 mg tablet of rilpivirine (Edurant). Oral rilpivirine must be taken with a meal. Initiate injections on the last day of oral lead-in or of your previous regimen. Initiation dose is 600 mg CAB-LA + 900 mg RPV LA (3 mL each). Then for every other month dosing, continue with this dose for month 2, and then every other month thereafter. For monthly dose, continue with a lower maintenance dose of 400 mg CAB-LA + 600 mg RPV LA (2 mL each) every month. Smaller dose may cause less pain or discomfort. See package insert for instructions on using the oral medications during planned or unplanned missed injections; oral medication should be taken until injections can be restarted. People may be given Cabenuva up to 7 days before or after the date scheduled for injections. See package insert for instructions on missed doses. Increased monitoring is recommended when CrCl is less than 30 mL/min. The effect of severe liver impairment on Cabenuva is unknown. Longer needles (not included in the dosing kit) may be required for people with a BMI (body mass index) greater than 30.
  • See Edurant; oral cabotegravir is not available separately
  • See package insert for more complete information on potential side effects and interactions.


ViiV Healthcare
viivhealthcare.com; cabenuva.com
(877) 844-8872


28-day oral lead-in provided at no cost
Loading dose and every other month dosing (600 mg/900 mg): $7,601.18

Maintenance dose (400 mg/600 mg): $5,067.46/month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments